%0 Journal Article %A Irene Pérez-Díez %A Marta R. Hidalgo %A Pablo Malmierca-Merlo %A Zoraida Andreu %A Rosa Farràs %A María de la Iglesia-Vayá %A Mariano Provencio %A Atocha Romero %A Francisco García-García %T Functional signatures in non-small-cell lung cancer: a systematic review and meta-analysis of sex-based differences in transcriptomic studies %D 2020 %R 10.1101/2020.08.24.20180026 %J medRxiv %P 2020.08.24.20180026 %X While studies have established the existence of differences in the epidemiological and clinical patterns of lung adenocarcinoma between male and female patients, we know relatively little regarding the molecular mechanisms underlying such sex-based differences. In this study, we explore said differences through a meta-analysis of transcriptomic data. We performed a meta-analysis of the functional profiling of nine public datasets that included 1,366 samples from Gene Expression Omnibus and The Cancer Genome Atlas databases. Meta-analysis results from data merged, normalized, and corrected for batch effect show an enrichment for Gene Ontology terms and Kyoto Encyclopedia of Genes and Genomes pathways related to the immune response, nucleic acid metabolism, and purinergic signaling. We discovered the overrepresentation of terms associated with the immune response, particularly with the acute inflammatory response, and purinergic signaling in female lung adenocarcinoma patients, which could influence reported clinical differences. Further evaluations of the identified differential biological processes and pathways could lead to the discovery of new biomarkers and therapeutic targets. Our findings also emphasize the relevance of sex-specific analyses in biomedicine, which represents a crucial aspect influencing biological variability in disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Fondo de Investigacion Sanitaria (ISCIII PI15-00209), GV/2020/186 and ISCIII PT17/0009/0015 FEDER.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All datasets are included in public repositories where everyone can download these data: GEO (https://www.ncbi.nlm.nih.gov/geo/), ArrayExpress (https://www.ebi.ac.uk/arrayexpress/) and TCGA (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used for the analyses described in this work is publicly available at GEO (https://www.ncbi.nlm.nih.gov/geo/) and the Genomic Data Commons Data Portal (TCGA, https://portal.gdc.cancer.gov/). The accession numbers of the GEO datasets downloaded are: GSE10072, GSE19188, GSE31210, GSE32863, GSE63459, GSE75037, GSE81089 and GSE87340. Only the samples associated with the project TCGA-LUAD were downloaded from the TCGA.https://bioinfo.cipf.es/metafun-nscls %U https://www.medrxiv.org/content/medrxiv/early/2020/11/18/2020.08.24.20180026.full.pdf